三阴性乳腺癌新辅助治疗的临床研究进展  

Neoadjuvant therapy for triple negative breast cancer:Clinical progress

作　　者：陈安莉 沈浩元 王舒 CHEN Anli;SHEN Haoyuan;WANG Shu(Jinzhou Medical University,Liaoning Jinzhou 121000,China;Affiliated Hospital of Wuhan University of Science and Technology(Xiaogan Central Hospital),Hubei Xiaogan 432100,China)

机构地区：[1]锦州医科大学,辽宁锦州121000 [2]武汉科技大学附属医院(孝感市中心医院),湖北孝感432100

出　　处：《现代肿瘤医学》2023年第3期566-571,共6页Journal of Modern Oncology

基　　金：湖北省卫生健康委员会联合基金(编号:WJ2019H246)。

摘　　要：三阴性乳腺癌(triple negative breast cancer,TNBC)是一种侵袭性很强的乳腺癌,由于缺乏有效的靶向治疗,预后不佳。乳腺癌新辅助治疗由于可增加降期、保乳、保腋的概率,同时还可筛选高危人群、获得药物敏感信息指导后续用药,因此已成为TNBC的重要治疗策略。本文综述了TNBC新辅助治疗的最新进展,包括铂类、免疫抑制剂、多腺苷二磷酸核糖聚合酶[poly(adenosine diphosphate-ribose)polymerase,PARP]抑制剂、磷脂酰肌醇-4,5-二磷酸3激酶催化亚基(PIK3CA)途径靶向治疗、肿瘤微环境(TME)靶向治疗。Triple negative breast cancer(TNBC)is a kind of invasive breast cancer,the prognosis is poor due to the lack of effective targeted therapy.Neoadjuvant therapy for breast cancer has become an important treatment strategy for TNBC,because it can increase the probability of breast and axillary preservation in the health period,and can also screen high-risk groups to obtain drug-sensitive information to guide subsequent drug use.In this review,the latest advances in neoadjuvant therapy for TNBC are reviewed,including targeted therapy of tumor microenvironment(TME)by the platinum-based immunosuppressant PARP inhibitor phosphatidlinositol-4,5-diphosphate 3 kinase catalytic subunit(PIK3CA)pathway.

关 键 词：三阴性乳腺癌 新辅助治疗 病理学完全缓解(pCR) 铂类 PARP抑制剂 免疫检查点抑制剂(ICI) 

分 类 号：R737.9[医药卫生—肿瘤]